Obinutuzumab: all 213 studies that test it

Page 1 of 3. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Not yet recruitingNCT07887061Phase 2
• Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingNCT07847957Phase 1/2
• Obinutuzumab in Systemic SclerosisNot yet recruitingNCT07842523Phase 2
• A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingNCT07799220Phase 2
• A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)Not yet recruitingNCT07767188Phase 3
• Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II TrialNot yet recruitingNCT07721363Phase 2
• Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingNCT07719556Phase 2
• A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)RecruitingNCT07710157Phase 2
• Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic LeukemiaNot yet recruitingNCT07690891Phase 2
• A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaNot yet recruitingNCT07674810Phase 2
• Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
• A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to RituximabRecruitingNCT07268521Phase 2
• Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
• Obinutuzumab in Adult Rituximab-Dependent Nephrotic SyndromeNot yet recruitingNCT07233330Phase 2
• Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity TrialRecruitingNCT07218510Phase 2
• Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingNCT07003464Phase 2
• LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisRecruitingNCT06978088Phase 2
• Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingNCT06967610Phase 2
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingNCT06943872Phase 3
• Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With PolyangiitisRecruitingNCT06940661Phase 2
• Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor BurdenRecruitingNCT06867536Phase 2
• MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingNCT06793189Phase 2
• OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)RecruitingNCT06781944Phase 3
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 2
• Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone LymphomaRecruitingNCT06566807Phase 2
• A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingNCT06561360Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
• Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06544785Phase 2
• Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasRecruitingNCT06513234Phase 2
• Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06428019Phase 3
• This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
• Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingNCT06357676Phase 1/2
• Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaRecruitingNCT06333262Phase 2
• Obinutuzumab in Treatment of Fibrillary GlomerulonephritisRecruitingNCT06295770Phase 2
• Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter SyndromeRecruitingNCT06186648Phase 2
• Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial ResponseRecruitingNCT06175000Phase 2
• Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaRecruitingNCT06108232Phase 2
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06094881Phase 2
• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingNCT06071871Phase 2
• Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06054776Phase 2
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune ThrombocytopeniaRecruitingNCT05995054Phase 2
• A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLRecruitingNCT05950997Not applicable
• Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT05943496Phase 1
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
• Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)RecruitingNCT05536349Phase 2
• Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaRecruitingNCT05336812Phase 2
• Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 AntibodyRecruitingNCT05045664Phase 3
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsRecruitingNCT05039619Phase 2
• Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease StatusRecruitingNCT04934930Phase 2
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04895436Phase 2
• Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingNCT04883437Phase 2
• Avo In R/R And Previously Untreated MCLRecruitingNCT04855695Phase 1/2
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067RecruitingNCT04787042Phase 1/2
• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingNCT04269902Phase 3
• Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT04169737Phase 2
• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT03516617Phase 2
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
• Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingNCT02393157Phase 2
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic SyndromeCompletedNCT05627557Phase 3Results posted
• PR3-AAV Resilient Remission or PRRRTerminatedNCT05376319Phase 2Results posted
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemActive, not recruitingNCT05211336Phase 1Results posted
• Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT05169658Phase 2Results posted
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedNCT05105841Phase 2Results posted
• Obinutuzumab in Primary FSGSCompletedNCT04983888Phase 2Results posted
• NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLCCompletedNCT04880863Phase 2Results posted
• A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular LymphomaTerminatedNCT04722601Phase 1/2Results posted
• Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 MutationCompletedNCT04285567Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisActive, not recruitingNCT04221477Phase 3Results posted
• Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular LymphomaTerminatedNCT03890289Phase 2Results posted
• Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT03872180Phase 2Results posted
• Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingNCT03863184Phase 2Results posted
• An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular LymphomaCompletedNCT03817853Phase 4Results posted
• Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte LeukemiaTerminatedNCT03759184Phase 1Results posted
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaTerminatedNCT03401853Phase 2Results posted
• Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell LymphomaTerminatedNCT03311126Phase 2Results posted
• Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasActive, not recruitingNCT03198026Phase 2Results posted
• A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03135262Phase 1/2Results posted
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaCompletedNCT03010358Phase 1/2Results posted
• Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02983617Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT02968563Phase 2Results posted
• Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular LymphomaCompletedNCT02871219Phase 2Results posted
• Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell TransplantationCompletedNCT02867384Phase 2Results posted
• Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT02736617Phase 2Results posted
• A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02729896Phase 1/2Results posted
• A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaCompletedNCT02631577Phase 1/2Results posted
• A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) ParticipantsTerminatedNCT02624986Phase 1/2Results posted
• A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02611323Phase 1/2Results posted
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesCompletedNCT02569476Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)CompletedNCT02550652Phase 2Results posted
• A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT02537613Phase 1Results posted
• A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell LymphomaCompletedNCT02529852Phase 1/2Results posted
• GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's LymphomaTerminatedNCT02495454Phase 2Results posted
• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLActive, not recruitingNCT02475681Phase 3Results posted
• Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT02427451Phase 1/2Results posted
• Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell LymphomaTerminatedNCT02420210Phase 2Results posted

← Obinutuzumab overview